Mesenchymal stem cell exosome therapy: current research status in the treatment of neurodegenerative diseases and the possibility of reversing normal brain aging DOI Creative Commons

Junjie Quan,

Qing Liu,

Pinghui Li

et al.

Stem Cell Research & Therapy, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 21, 2025

With the exacerbation of aging population trend, a series neurodegenerative diseases caused by brain have become increasingly common, significantly impacting daily lives elderly and imposing heavier burdens on nations societies. Brain is complex process involving multiple mechanisms, including oxidative stress, apoptosis damaged neuronal cells, chronic inflammation, mitochondrial dysfunction, research into new therapeutic strategies to delay has gradually focus in recent years. Mesenchymal stem cells (MSCs) been widely used cell therapy due their functions such as antioxidative anti-inflammation, tissue regeneration. However, accompanying safety issues immune rejection, tumor development, pulmonary embolism cannot be avoided. Studies shown that using exosome derived from mesenchymal (MSC-Exo) for treatment safe effective method. It not only effects but also avoids risks associated with therapy. Therefore, exploring normal mechanism MSC-Exo feasible. This review summarizes characteristics clinical progress diseases, aiming explore possibility potential mechanisms reversing aging.

Language: Английский

Reprogramming macrophages via immune cell mobilized hydrogel microspheres for osteoarthritis treatments DOI Creative Commons

Pengcheng Xiao,

Xiaoyu Han, Yanran Huang

et al.

Bioactive Materials, Journal Year: 2023, Volume and Issue: 32, P. 242 - 259

Published: Oct. 12, 2023

Regulating macrophage activation precisely is crucial in treating chronic inflammation osteoarthritis (OA). However, the stable pro-inflammatory state and deep distribution of macrophages vivo pose a great challenge to treatment. In this study, inspired by innate immune, immune cell mobilized hydrogel microspheres were constructed microfluidic methods load chemokines, antibodies engineered membrane vesicles (sEVs) via covalent non-covalent junctions. The microspheres, based on mixture streptavidin grafted hyaluronic acid methacrylate (HAMA-SA) Chondroitin sulfate (ChSMA) (HCM), can recruit, capture reprogram proinflammatory joint cavity improve inflammatory microenvironment. vitro experiments demonstrated that had excellent recruitment, capture, reprogramming abilities. Pro-inflammatory be transformed into anti-inflammatory with an efficiency 88.5 %. Animal also revealed significant reduction synovial cartilage matrix degradation OA. Therefore, may effective treatment OA for future.

Language: Английский

Citations

50
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies DOI Open Access

Francesca R. Buccellato,

Marianna D’Anca, Gianluca Martino Tartaglia

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(18), P. 13900 - 13900

Published: Sept. 9, 2023

In an ever-increasing aged world, Alzheimer’s disease (AD) represents the first cause of dementia and one chronic diseases in elderly people. With 55 million people affected, WHO considers AD to be a with public priority. Unfortunately, there are no final cures for this pathology. Treatment strategies aimed mitigate symptoms, i.e., acetylcholinesterase inhibitors (AChEI) N-Methyl-D-aspartate (NMDA) antagonist Memantine. At present, best approaches managing seem combine pharmacological non-pharmacological therapies stimulate cognitive reserve. Over last twenty years, number drugs have been discovered acting on well-established biological hallmarks AD, deposition β-amyloid aggregates accumulation hyperphosphorylated tau protein cells. Although previous efforts disappointed expectations, new era treating has working its way recently. The Food Drug Administration (FDA) gave conditional approval disease-modifying therapy (DMT) treatment aducanumab, monoclonal antibody (mAb) designed against Aβ plaques oligomers 2021, January 2023, FDA granted accelerated second antibody, Lecanemab. This review describes ongoing clinical trials DMTs therapies. We will also present future scenario based biomarkers that can detect preclinical or prodromal stages, identify at risk developing allow early curative treatment.

Language: Английский

Citations

45
Biomimetic Nanovesicles as a Dual Gene Delivery System for the Synergistic Gene Therapy of Alzheimer’s Disease DOI

Sujun Jiang,

Guoen Cai, Zhimin Yang

et al.

ACS Nano, Journal Year: 2024, Volume and Issue: 18(18), P. 11753 - 11768

Published: April 22, 2024

The association between dysfunctional microglia and amyloid-β (Aβ) is a fundamental pathological event increases the speed of Alzheimer's disease (AD). Additionally, pathogenesis AD intricate single drug may not be enough to achieve satisfactory therapeutic outcome. Herein, we reported facile effective gene therapy strategy for modulation function intervention Aβ anabolism by ROS-responsive biomimetic exosome-liposome hybrid nanovesicles (designated as TSEL). codelivery β-site amyloid precursor protein cleaving enzyme-1 (BACE1) siRNA (siBACE1) TREM2 plasmid (pTREM2) efficiently penetrate blood-brain barrier enhance accumulation at lesions with help exosomes homing ability angiopep-2 peptides. Specifically, an upregulation expression can reprogram from pro-inflammatory M1 phenotype anti-inflammatory M2 while also restoring its capacity phagocytose nerve repair function. In addition, reduces production plaques source knocking out BACE1 gene, which expected further effect AD. in vivo study suggests that TSEL through synergistic two drugs ameliorate APP/PS1 mice cognitive impairment regulating activated microglial phenotype, reducing Aβ, preventing retriggering neuroinflammation. This employs delivery dual nucleic acids, achieving AD, thus offering more options treatment

Language: Английский

Citations

25
Emerging Strategies for Revascularization: Use of Cell-Derived Extracellular Vesicles and Artificial Nanovesicles in Critical Limb Ischemia DOI Creative Commons

Vijay Murali Ravi Mythili,

Ramya Lakshmi Rajendran, Arun Renganathan

et al.

Bioengineering, Journal Year: 2025, Volume and Issue: 12(1), P. 92 - 92

Published: Jan. 20, 2025

Critical limb ischemia (CLI) poses a substantial and intricate challenge in vascular medicine, necessitating the development of innovative therapeutic strategies to address its multifaceted pathophysiology. Conventional revascularization approaches often fail adequately complexity CLI, identification alternative methodologies. This review explores uncharted territory beyond traditional therapies, focusing on potential two distinct yet interrelated entities: cell-derived extracellular vesicles (EVs) artificial nanovesicles. Cell-derived EVs are small membranous structures naturally released by cells, nanovesicles artificially engineered nanosized vesicles. Both these represent promising avenues for intervention. They act as carriers bioactive cargo, including proteins, nucleic acids, lipids, that can modulate cellular responses associated with ischemic tissue repair angiogenesis. also assesses evolving landscape CLI through unique perspective The spans spectrum from early preclinical investigations latest translational advancements, providing comprehensive overview current state research this emerging field. These groundbreaking vesicle therapies hold immense revolutionizing treatment paradigms.

Language: Английский

Citations

2
The role of exosomes in diagnosis, pathophysiology, and management of Alzheimer's Disease DOI Creative Commons

Rajni Daksh,

Meby Susan Mathew,

Aan Mery Bosco

et al.

Biochemical and Biophysical Research Communications, Journal Year: 2025, Volume and Issue: 754, P. 151526 - 151526

Published: Feb. 22, 2025

Language: Английский

Citations

2
Amyloid Precursor Protein and Alzheimer’s Disease DOI Open Access

Kseniia S. Orobets,

Andrey L. Karamyshev

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(19), P. 14794 - 14794

Published: Sept. 30, 2023

Alzheimer's disease (AD) is one of the most common neurodegenerative disorders associated with age or inherited mutations. It characterized by severe dementia in late stages that affect memory, cognitive functions, and daily life overall. AD progression linked to accumulation cytotoxic amyloid beta (Aβ) hyperphosphorylated tau protein combined other pathological features such as synaptic loss, defective energy metabolism, imbalances protein, metal homeostasis. Several treatment options for are under investigation, including antibody-based therapy stem cell transplantation. Amyloid precursor (APP) a membrane considered play main role pathology. known APP physiological conditions follows non-amyloidogenic pathway; however, it can proceed an amyloidogenic scenario, which leads generation extracellular deleterious Aβ plaques. Not all steps biogenesis clear so far, these questions should be addressed future studies. complex chronic many factors contribute progression.

Language: Английский

Citations

33
Advances in the study of exosomes derived from mesenchymal stem cells and cardiac cells for the treatment of myocardial infarction DOI Creative Commons
Yu‐Chang Liu,

Minrui Wang,

Yu Yang

et al.

Cell Communication and Signaling, Journal Year: 2023, Volume and Issue: 21(1)

Published: Aug. 14, 2023

Acute myocardial infarction has long been the leading cause of death in coronary heart disease, which is characterized by irreversible cardiomyocyte and restricted blood supply. Conventional reperfusion therapy can further aggravate injury. Stem cell therapy, especially with mesenchymal stem cells (MSCs), emerged as a promising approach to promote cardiac repair improve function. MSCs may induce these effects secreting exosomes containing therapeutically active RNA, proteins lipids. Notably, normal function depends on intracardiac paracrine signaling via exosomes, secreted partially reflect changes during so analyzing vesicles provide valuable insights into pathology well guide development new treatments. The present review examines how produced influence injury after serve therapies against such Video Abstract.

Language: Английский

Citations

29
Mesenchymal Stem Cell-Derived Exosomes as Drug Delivery Vehicles in Disease Therapy DOI Open Access

Wenzhe Zhao,

Kaixuan Li,

Liangbo Li

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7715 - 7715

Published: July 14, 2024

Exosomes are small vesicles containing proteins, nucleic acids, and biological lipids, which responsible for intercellular communication. Studies have shown that exosomes can be utilized as effective drug delivery vehicles to accurately deliver therapeutic substances target tissues, enhancing effects reducing side effects. Mesenchymal stem cells (MSCs) a class of widely used tissue engineering, regenerative medicine, immunotherapy. derived from MSCs special immunomodulatory functions, low immunogenicity, the ability penetrate tumor high yield, expected engineered into efficient systems. Despite promising promise MSC-derived exosomes, exploring their optimal preparation methods, drug-loading modalities, potential remains challenging. Therefore, this article reviews related characteristics, application, risks systems in order find breakthroughs.

Language: Английский

Citations

15
Mesenchymal stem cell-derived extracellular vesicles: A novel promising neuroprotective agent for Alzheimer's disease DOI
Jun Chang, Zihang Feng, Yujiao Li

et al.

Biochemical Pharmacology, Journal Year: 2024, Volume and Issue: 222, P. 116064 - 116064

Published: Feb. 17, 2024

Language: Английский

Citations

10
Peripheral extracellular vesicles in neurodegeneration: pathogenic influencers and therapeutic vehicles DOI Creative Commons
Xixi Liu, Lu Shen,

Meidan Wan

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: April 12, 2024

Abstract Neurodegenerative diseases (NDDs) such as Alzheimer’s disease, Parkinson’s and amyotrophic lateral sclerosis epitomize a class of insidious relentless neurological conditions that are difficult to cure. Conventional therapeutic regimens often fail due the late onset symptoms, which occurs well after irreversible neurodegeneration has begun. The integrity blood-brain barrier (BBB) further impedes efficacious drug delivery central nervous system, presenting formidable challenge in pharmacological treatment NDDs. Recent scientific inquiries have shifted focus toward peripheral biological systems, investigating their influence on neuropathology through lens extracellular vesicles (EVs). These vesicles, distinguished by ability breach BBB, emerging dual operatives context NDDs, both conveyors pathogenic entities prospective vectors for agents. This review critically summarizes burgeoning evidence role extracerebral EVs, particularly those originating from bone, adipose tissue, gut microbiota, modulating brain pathophysiology. It underscores duplicity potential EVs modulators disease progression suggests novel vehicles targeted delivery, positing transformative impact future landscape NDD strategies. Search strategy A comprehensive literature search was conducted using PubMed, Web Science, Scopus January 2000 December 2023. combined following terms Boolean operators: “neurodegenerative disease” OR “Alzheimer’s “Parkinson’s “Amyotrophic sclerosis” AND “extracellular vesicles” “exosomes” “outer membrane “drug systems” “blood-brain barrier”. MeSH were employed when searching PubMed refine results. Studies included if they published English, involved human subjects, focused origins specifically association with related osteoporosis, metabolic syndrome, dysbiosis. Articles excluded did not address NDDs or discuss applications. titles abstracts retrieved articles screened dual-review process ensure relevance accuracy. reference lists selected also examined identify additional relevant studies.

Language: Английский

Citations

10